Seyed Arad Moghadasi

Seyed Arad Moghadasi

Auto-generated profile, based on publicly available information

Seyed Arad Moghadasi

University of Minnesota

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2023 in Science Advances
Verified
Journal Article
Closed access
SMSeyed Arad Moghadasi
Seyed Arad Moghadasi
EHEmmanuel Heilmann
Emmanuel Heilmann
Ahmed KhalilAhmed Khalil
Ahmed Khalil
CNChristina Nnabuife
Christina Nnabuife
FKFiona Kearns
Fiona Kearns
RHReuben Harris
Reuben Harris
Vaccines and drugs have helped reduce disease severity and blunt the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, ongoing virus transmission, continuous evolution, and increasing selective pressures have the potential to yield viral variants capable of resisting these interventions. Here, we investigate the susceptibility of natural variants of the main protease [M pro ; 3C-like protease (3CL pro )] of SARS-CoV-2 to protease inhibitors. Multiple single amino acid changes in M pro confer resistance to nirmatrelvir (the active component of Paxlovid). An additional clinical-stage inhibitor, ensitrelvir (Xocova), shows a different resistance mutation profile. Importantly, phylogenetic analyses indicate that several of these resistant variants have pre-existed the introduction of these drugs into the human population and are capable of spreading. These results encourage the monitoring of resistance variants and the development of additional protease inhibitors and other antiviral drugs with different mechanisms of action and resistance profiles for combinatorial therapy.

11 January 2023 in Science Translational Medicine
Verified
Journal Article
Open access
EHEmmanuel Heilmann
Emmanuel Heilmann
FCFrancesco Costacurta
Francesco Costacurta
SMSeyed Arad Moghadasi
Seyed Arad Moghadasi
CYChengjin Ye
Chengjin Ye
Matteo PavanMatteo Pavan
Matteo Pavan
Dorothee Von LaerDorothee Von Laer
Dorothee Von Laer
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first protease inhibitor specifically developed against the SARS-CoV-2 protease 3CL pro that has been licensed for clinical use. To identify mutations that confer resistance to this protease inhibitor, we engineered a chimeric vesicular stomatitis virus (VSV) that expressed a polyprotein composed of the VSV glycoprotein (G), the SARS-CoV-2 3CL pro , and the VSV polymerase (L). Viral replication was thus dependent on the autocatalytic processing of this precursor protein by 3CL pro and release of the functional viral proteins G and L, and replication of this chimeric VSV was effectively inhibited by nirmatrelvir. Using this system, we applied nirmatrelvir to select for resistance mutations. Resistance was confirmed by retesting nirmatrelvir against the selected mutations in additional VSV-based systems, in an independently developed cellular system, in a biochemical assay, and in a recombinant SARS-CoV-2 system. We demonstrate that some mutants are cross-resistant to ensitrelvir and GC376, whereas others are less resistant to these compounds. Furthermore, we found that most of these resistance mutations already existed in SARS-CoV-2 sequences that have been deposited in the NCBI and GISAID databases, indicating that these mutations were present in circulating SARS-CoV-2 strains.

25 September 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
FCFrancesco Costacurta
Francesco Costacurta
ADAndrea Dodaro
Andrea Dodaro
DBDavid Bante
David Bante
HSHelge Schoeppe
Helge Schoeppe
BSBernhard Sprenger
Bernhard Sprenger
EHEmmanuel Heilmann
Emmanuel Heilmann
Nirmatrelvir was the first protease inhibitor (PI) specifically developed against the SARS-CoV-2 main protease (3CL pro /M pro ) and licensed for clinical use. As SARS-CoV-2 continues to spread, variants resistant to nirmatrelvir and other currently available treatments are likely to arise. This study aimed to identify and characterize mutations that confer resistance to nirmatrelvir. To safely generate M pro resistance mutations, we passaged a previously developed, chimeric vesicular stomatitis virus (VSV-M pro ) with increasing, yet suboptimal concentrations of nirmatrelvir. Using Wuhan-1 and Omicron M pro variants, we selected a large set of mutants. Some mutations are frequently present in GISAID, suggesting their relevance in SARS-CoV-2. The resistance phenotype of a subset of mutations was characterized against clinically available PIs (nirmatrelvir and ensitrelvir) with cell-based and biochemical assays. Moreover, we showed the putative molecular mechanism of resistance based on in silico molecular modelling. These findings have implications on the development of future generation M pro inhibitors, will help to understand SARS-CoV-2 protease-inhibitor-resistance mechanisms and show the relevance of specific mutations in the clinic, thereby informing treatment decisions. Teaser: Understanding how SARS-CoV-2 could counter the antiviral drug nirmatrelvir and what it means for the future of COVID-19 treatment.

23 August 2024 in SLAS Discovery
Verified
Journal Article
Open access
RDRenee Delgado
Renee Delgado
JVJyoti Vishwakarma
Jyoti Vishwakarma
SMSeyed Arad Moghadasi
Seyed Arad Moghadasi
YOYuka Otsuka
Yuka Otsuka
JSJustin Shumate
Justin Shumate
RHReuben Harris
Reuben Harris
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2, SARS2) is responsible for the COVID-19 pandemic and infections that continue to affect the lives of millions of people worldwide, especially those who are older and/or immunocompromised. The SARS2 main protease enzyme, Mpro (also called 3C-like protease, 3CLpro), is a bona fide drug target as evidenced by potent inhibition with nirmatrelvir and ensitrelvir, the active components of the drugs Paxlovid and Xocova, respectively. However, the existence of nirmatrelvir and ensitrelvir-resistant isolates underscores the need to develop next-generation drugs with different resistance profiles and/or distinct mechanisms of action. Here, we report the results of a high-throughput screen of 649,568 compounds using a cellular gain-of-signal assay. In this assay, Mpro inhibits expression of a luciferase reporter, and 8,777 small molecules were considered hits by causing a gain in luciferase activity 3x SD above the sample field activity (6.8% gain-of-signal relative to 100 µM GC376). Single concentration and dose-response gain-of-signal experiments confirmed 3,522/8,762 compounds as candidate inhibitors. In parallel, all initial high-throughput screening hits were tested in a peptide cleavage assay with purified Mpro and only 39/8,762 showed inhibition. Importantly, 19/39 compounds (49%) re-tested positive in both SARS2 assays, including two previously reported Mpro inhibitors, demonstrating the efficacy of the overall screening strategy. This approach led to the rediscovery of known Mpro inhibitors such as calpain inhibitor II, as well as to the discovery of novel compounds that provide chemical information for future drug development efforts.

27 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSeyed Arad Moghadasi
Seyed Arad Moghadasi
RBRayhan G. Biswas
Rayhan G. Biswas
DHDaniel A. Harki
Daniel A. Harki
RHReuben Harris
Reuben Harris
Resistance to nirmatrelvir (Paxlovid) has been shown by multiple groups and may already exist in clinical SARS-CoV-2 isolates. Here a panel of SARS-CoV-2 main protease (M pro ) variants and a robust cell-based assay are used to compare the resistance profiles of nirmatrelvir, ensitrelvir, and FB2001. The results reveal distinct resistance mechanisms (“fingerprints”) and indicate that these next-generation drugs have the potential to be effective against nirmatrelvir-resistant variants and vice versa .